期刊
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
卷 77, 期 1, 页码 34-37出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/FJC.0000000000000916
关键词
type 2 diabetes; major adverse cardiovascular events; SGLT2is; GLP-1 RAs; cardiovascular disease; heart failure; chronic kidney disease; network meta-analysis
This study identified that different glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors have varying efficacy in preventing major adverse cardiovascular events in type 2 diabetes patients with or without cardiorenal disease. Subcutaneous semaglutide and albiglutide were found to be most effective in diabetes with cardiovascular disease, albiglutide in diabetes with heart failure, and canagliflozin and liraglutide in diabetes with chronic kidney disease.
The comparative efficacy of different glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular events (MACE) in type 2 diabetes with or without cardiorenal disease is undefined. PubMed and Embase were searched for relevant randomized trials. We conducted network meta-analysis within the Bayesian framework. Effect sizes were measured using hazard ratio (HR) and 95% confidence interval (CI). We calculated surface under the cumulative ranking curve (SUCRA) values to rank drug interventions for different type 2 diabetic subgroups. Albiglutide (HR 0.76, 95% CI 0.63-0.93) and subcutaneous semaglutide (HR 0.71, 95% CI 0.52-0.95), with the maximum SUCRA values, significantly reduced MACE versus lixisenatide in people with diabetes with cardiovascular disease; albiglutide (HRs: 0.69 and 0.72), with the maximum SUCRA value, significantly reduced MACE versus dapagliflozin and exenatide in people with diabetes with heart failure; and canagliflozin (HRs: 0.72 and 0.72) and liraglutide (HRs: 0.68 and 0.68), with the maximum SUCRA values, significantly reduced MACE versus exenatide and lixisenatide in people with diabetes with chronic kidney disease. In preventing MACE in type 2 diabetes, subcutaneous semaglutide and albiglutide are most effective for diabetes with cardiovascular disease, albiglutide is most effective for diabetes with heart failure, and canagliflozin and liraglutide are most effective for diabetes with chronic kidney disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据